Attenuated Salmonella typhimurium accumulated and multiplied preferentially in tumors as compared to in normal tissues after being injected intravenously into tumor-bearing mice and rats. VNP20009, an attenuated strain with msbB-purl- deletions, is being evaluated in Phase I trials in cancer patients. VNP20009 induced significant tumor growth inhibition in addition to accumulated to high levels in tumors. Some of the closely related strains, however, did not inhibit tumor growth although they accumulated to similar levels, as did VNP20009. The main goal for this proposal is to evaluate differential protein expression in two pairs of bacteria and to identify components that cause tumor growth inhibition by combining the proteomic and genomic approach. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA096292-01A1
Application #
6583589
Study Section
Special Emphasis Panel (ZRG1-SSS-1 (10))
Program Officer
Fu, Yali
Project Start
2003-02-01
Project End
2003-07-31
Budget Start
2003-02-01
Budget End
2003-07-31
Support Year
1
Fiscal Year
2003
Total Cost
$100,000
Indirect Cost
Name
Vion Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511